IL1B and diabetes mellitus: Wogonin has been proved to mitigate inflammation, hyperglycemia, and dyslipidemia, exerting beneficial effects on diabetes and diabetes-associated diseases with elevated adiponectin expression, decreased IL-1β, IL-6, and TNF-α production, and inhibited Th17 differentiation and NF-κB signaling (Bak et al., 2014; Takagi et al., 2014; Wang W. et al., 2015; Khan et al., 2016).